Clinuvel Pharmaceuticals' drug SCENESSE® (afamelanotide) has received Health Canada's Notice of Compliance for preventing phototoxicity in adults with erythropoietic protoporphyria (EPP), a rare metabolic disorder causing severe skin reactions to light. This approval allows Clinuvel to market SCENESSE® in Canada, joining previous approvals in Europe, the US, and Australia. SCENESSE® is the only approved systemic treatment for EPP, with a proven long-term safety profile backed by over 21,000 doses administered globally. The drug works by increasing melanin production to protect skin from light damage, offering significant benefit to patients with limited treatment options.
During week 28 of 2026 (July 6-10), Sampo Oyj bought back a total of 35,203 of its own A-shares across multiple markets at a weighted average price of €9.32 per share. This buyback is part of a larger program authorized by the company's annual genera...
John Crane UK Limited has achieved Broad-Based Black Economic Empowerment (B-BBEE) Level One status in South Africa, the highest recognition under the country's transformation framework. This milestone enhances John Crane's position as a preferred su...
Chery Group showcased the FREELANDER 8 SUV at the Abu Dhabi Investment Forum, highlighting its Super Intelligent Valet Parking (SIVP) system. This smart parking technology allows remote parking and vehicle retrieval via a mobile app, designed to ease...
XRP offers fast, low-cost international transfers and saw regulatory clarity in 2025 when Ripple settled an SEC lawsuit with a $125 million fine, confirming XRP is not a security on public exchanges. Ripple holds about 32.6 billion XRP in escrow, rel...
Brave Bison has proposed a £43.1 million cash-and-share offer to acquire System1 Group PLC, aiming to merge the two into a marketing data and technology group with £79 million in pro-forma net revenue. The offer values System1 shares at about 327p, a...
